All In Biotech

NDA 019732 · Abbvie Endocrine INC

Lupron Depot

Leuprolide Acetate · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: Aug 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Jan 26, 1989

Approved uses

2

Original approval plus efficacy supplements

Registered trials

457

123 Phase 3, 53 recruiting

FAERS reports

29,123

17,188 serious, 4,144 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 15, 2026.

LUPRON DEPOT 7.5 mg for 1-month administration, 22.5 mg for 3-month administration, 30 mg for 4-month administration, and 45 mg for 6-month administration (leuprolide acetate) are indicated for the treatment of advanced prostate cancer. LUPRON DEPOT is a gonadotropin releasing hormone (GnRH) agonist indicated for: treatment of advanced prostate cancer. ( 1 )

Mechanism: Leuprolide acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal studies indicate that following an initial stimulation, continuous administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect was reversible upon discontinuation of drug therapy. Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormone dependent tumors (prostatic tumors in Noble and Dunning male rats and DMBA-induced mammary tumors in female rats) as well as atrophy of the reproductive organs.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LUPRON DEPOT · LEUPROLIDE ACETATE 7.5MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Leuprolide" as an intervention, any sponsor and status, largest first.

All 457 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hot flush3,487
  • death2,333
  • fatigue1,923
  • headache1,462
  • pain1,285
  • drug ineffective1,187
  • nausea1,180
  • arthralgia1,082
  • asthenia998
  • abdominal pain942
  • off label use938
  • vaginal haemorrhage878

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004127
2005119
2006106
2007141
2008506
2009978
20101,324
20111,582
20121,181
20131,670
20142,641
20152,663
20161,865
20171,342
20181,384
20191,495
20201,350
20211,527
20221,854
20231,614
20241,500
20251,148
20261,006

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lupron Depot (Leuprolide Acetate)

2024 spending

$164M

Beneficiaries

11,482

31,645 claims

Per beneficiary

$14,283

$5,177.85 per unit

View as table
YearSpending
2020$82,608,206
2021$82,903,168
2022$107,502,481
2023$128,884,249
2024$163,997,487

Part B: Lupron Depot* (Leuprolide Acetate*) · HCPCS J1950

2024 spending

$11.2M

Beneficiaries

1,111

4,163 claims

Per beneficiary

$10,111

2024 ASP limit $1,608.08 per unit

View as table
YearSpending
2020$6,502,353
2021$6,456,999
2022$8,232,155
2023$10,345,855
2024$11,233,617

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 569 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.